Trends

The number of specialty drugs and biologics making it to market slipped from 25 in 2012 to 13 last year. Cancer continues to be a hotbed of specialty drug development. Of the 13 specialty drugs and biologics approved last year, nine carry oncology indications and hefty price tags. None were chemotherapies.

Our most popular topics on Managedcaremag.com


Leave a Comment